- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06139510
Predictors of Pain in Sickle Cell Disease
Predictors of Pain Severity and Pain-Related Outcomes in Individuals With Sickle Cell Disease
Sickle cell disease is a painful inherited disorder that affects approximately 100,000 people in the United States, and more than half of these individuals develop chronic or persistent pain that is often severe and disabling. The factors that predict whether an individual with sickle cell disease will develop severe, disabling pain are unclear. The goal of this project is to identify the factors that predict severe pain outcomes in individuals living with sickle cell disease in order to improve pain management strategies and guide future studies of non-opioid therapies for treatment of their pain.
Participants who agree to enroll in this study will be asked to participate in a virtual and then an in-person study visit for their full initial study assessment. They will answer survey questions during the virtual visit, and will be asked to complete several types of standard testing to understand how their body handles pain during the in-person visit. After completing the virtual and in-person sessions, participants will receive text or electronic medical record messages with brief survey (will take less than 8 minutes to complete) on their pain experiences every three months until the study is completed (or up to 48 months for people who are enrolled at the beginning of the study).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Martha Kenney, MD
- Phone Number: 9196814877
- Email: martha.kenney@duke.edu
Study Contact Backup
- Name: Nirmish Shah, MD
- Phone Number: 1919 668 5178
- Email: nirmish.shah@duke.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
All participants must be between 15 and 40 years old and must be able to provide informed, written consent (for adults) or parental consent (for participants younger than 18 years).
Inclusion Criteria:
- Diagnosis of sickle cell disease (documentation of SS, SC, S beta + thalassemia, S beta + thalassemia) is required
- Participants must have had at least one sickle cell related pain episode that required treatment with opioids at home or in the hospital 12 months prior to recruitment
- Participants who are on chronic analgesics (NSAID, acetaminophen) or opioids should be on a stable dose for 4 weeks prior to recruitment.
Exclusion Criteria:
- Age less than 15 or greater than 40 years
- Participants lacking the cognitive or mental capacity to assent to and complete study procedures
- Pregnant females
- Participants with history of a stroke with ongoing physical impairment that prevents participation in study procedures.
- Participants with history of severe vaso-occlusive pain crisis resulting in either evaluation in an emergency department or admission to a hospital two weeks prior to study enrollment.
- Current or active infection
- Any condition that the principle investigator considers would preclude or bias participation in the study, such as (1) neuropathy from diabetes or other causes, (2) active avascular necrosis requiring treatment for pain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Individuals living with sickle cell disease
Participants living with sickle cell disease will undergo standardized testing called quantitative sensory testing.
Quantitative sensory testing measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
|
Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain pain severity
Time Frame: At baseline and every three months while enrolled in the study, up to 48 months
|
Will be determined by answering the severity subscale of the Brief Pain Inventory
|
At baseline and every three months while enrolled in the study, up to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in psychological distress
Time Frame: At baseline and every three months while enrolled in the study, up to 48 months
|
Will be determined based on answers to the anxiety and depression subscales of the PROMIS-29 questionnaire.
A composite score of the subscales will be reported.
|
At baseline and every three months while enrolled in the study, up to 48 months
|
Change in pain interference
Time Frame: At baseline and every three months while enrolled in the study, up to 48 months
|
Will be determined based on answers to the pain interference subscale of the PROMIS-29 questionnaire.
|
At baseline and every three months while enrolled in the study, up to 48 months
|
Change in physical function
Time Frame: At baseline and every three months while enrolled in the study, up to 48 months
|
Will be determined based on answers to the physical function subscale of the PROMIS-29 questionnaire.
|
At baseline and every three months while enrolled in the study, up to 48 months
|
Change in healthcare utilization for pain
Time Frame: At baseline and every three months while enrolled in the study, up to 48 months
|
Will be determined based on answers to the PhenX Frequency of Sickle Cell Pain Episodes Per year questionnaire.
|
At baseline and every three months while enrolled in the study, up to 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Martha Kenney, MD, Duke University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00112024
- 1K01HL169339-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
Clinical Trials on Quantitative sensory testing
-
Julia FinkelCompletedSCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)United States
-
University Hospital, BrestCompletedSensitive SkinFrance
-
Region Örebro CountyAalborg UniversityCompleted
-
University of California, Los AngelesCompleted
-
University GhentRecruiting
-
Walton Centre NHS Foundation TrustActive, not recruitingFacial PainUnited Kingdom
-
Spine Centre of Southern DenmarkUniversity of Southern DenmarkCompleted
-
University of Sao PauloCompletedNeuralgia | Facial Pain | Comorbidity
-
Ahram Canadian UniversityRecruitingCarpal Tunnel SyndromeEgypt